

**UTT Ltd.** is on a mission to dramatically enhance the efficacy of bladder medications by providing solutions for prolonged topical exposure to the bladder tissue. With three 3 proprietary technologies for fast relief of bladder disorders, UTT aims to offer 1] a paradigm change in topical drug treatments; and 2] a 1st dignified incontinence-control device.

## Prevalant Bladder Disorders

### Prostate Cancer

- 2nd deadliest cancer in US
- ~300,00 new cases in the US annually

### Bladder Cancer

- Affects 800,000 patients/ yr in US
- 17,000 deaths/yr in the US

### Urinary Tract Inflammation

- Affects over 50% of the global population

### Incontinence

- Affects over 25M people in US
- 75% of women affected

### Overactive Bladder (OAB)

- Affects 40% of women
- 30% of men in US

### Interstitial Cystitis (IC)

- Affects between 4-12M people globally
- Symptoms include bladder and pelvic pain, sexual complications



## Ineffective Existing Medication Treatments

### Most medications have non-optimal bioavailability due to ineffective delivery

- Oral drugs have poor absorption in the bladder
- Topical drugs are washed out of the bladder shortly after instillation



## PROPRIETARY SOLUTIONS

### ① UTT Sponge

Enables the use of existing medications to topical delivery

- Sponge-based topical drug treatments for bladder inflammations, overactive bladder, urinary incontinence and bladder cancer

### ② Chemo-Gel

Injectable gel, loaded with chemotherapy for prolonged release

- Chemo-Gel implemented for a minimally-invasive, non-surgical treatment of prostate cancer

### ③ Leakage-Control Device (ULC)

An in-dwelling magnetic bladder buoy

- A magnetic floating buoy that is inserted into the bladder and is compressed against the bladder sphincter to provide a urine leakage barrier.

# UTT Market Outlook




2023 Urinary Disease  
Global Market


**\$6B**

**3.8% CAGR**

## Global Market Size by 2030



## Key Milestones



## A Proven Team

### Founders & Management Team



**Eli Ben Haroosh**  
CEO, Founder, & Director  
*Stickit, Vonetize, Premier-Dead Sea*



**Asher Holzer, Ph.D**  
President, Founder  
*UroGen, InspireMD, BioSig Technologies, TheraCoat*



**Talya Lankry**  
Director(?)  
*Armored Corps, General Staff*



**Gad Benett**  
Advisor  
*Paulina Ben-Ami, Tectonic, Vicinity*



**Zeev Schmelzer, PhD**  
Advisor

### Advisors & Board of Directors



**Eng. Yosh Dollberg**  
Director  
*UroGen, Pontifax Group,*



**Lior Neshet, M.D.**  
Director  
*SUMC, BenGurion University*



**David Margel, MD, PhD**  
Director  
*Raphael Hospital, Rabin Medical Center,*



**Shira Chatumi, PhD**  
Director  
*MYMC, Maccabi Health Services*



**Susan Alpert, PhD, MD**  
Director  
*SFA Regulatory, LLC, Medtronic, US FDA*